ComparativeAnticoagulantandPlateletModulatoryEffectsofEnoxaparinandSulodexide
CaferAdiguzel,MD,OmerIqbal,MD,
DebraHoppensteadt,PhD,WalterJeske,PhD,
JosephineCunanan,MD,EvangelosLitinas,MD,HeZhu,MD,JeanineM.Walenga,PhD,andJawedFareed,PhD
Sulodexiderepresentsanovelantithromboticagentwithmultiplesitesofactiononbloodcoagulationandvascularprocesses.Thepurposeofthisstudywastocomparesulodexideandenoxaparinonanticoagulanteffects,tissuefactor(TF)-inducedactivationofplate-lets,inhibitionofmicroparticlegenerationandtoinvestigatetheireffectonheparin-inducedplateletaggregation(HIPA).Sulodexidewascomparedwithenoxaparinatequigravimetricconcentrations.Whencomparedtoenoxaparin,sulodexideproducedastron-geranticoagulanteffectintheprothrombintime(PT),activatedpartialthromboplastintime(APTT),Heptest,andthrombintime(TT)assays.Inaddition,sulodexidehadastrongerinhibitoryeffectonTF-mediatedmicroparticlegeneration(IC50¼2.8mg/mL),P-selectinexpression(IC50¼4.8mg/ml),andpla-teletaggregateformation(IC50¼8.5mg/mL)compared
andAppliedNumber5
501-511
#2009Author(s)tohigherIC50valueswithenoxaparin.Sulodexideandenoxaparinexhibitedasimilareffectonheparin-inducedthrombocytopenia(HIT)antibody-mediatedplateletactivationHIPAassays.Theseresultssuggestthatsulodexideisarelativelystrongeranticoagulantagentthanenoxaparin.Sulodexideissubcutaneouslyabsorbed.ItsabilitytoinhibitTF-mediatedplateletactivationmaycontributetotheobservedtherapeuticeffectsofsulodexideinmicrovascularvasculopathysuchasdiabeticnephropathy.Theseresultsalsosug-gestthatinhibitionofTFactivationofplateletsbysulo-dexidemaybeindependentofitsanticoagulanteffects.Theseresultswarrantfurtherinvestigationofsulodex-ideinadditionalpreclinicalandclinicalstudies.Keywords:sulodexide;enoxaparin;plateletmicropar-ticle;plateletactivation;plateletfactor4antibodies
Introduction
Thefirstlow-molecular-weightheparin(LMWH)wasintroducedforthetreatmentofvenousthrom-boembolism(VTE)morethan20yearsago.1Enoxa-parinisaLMWH,whichispreparedbythedepolymerizationofunfractionatedheparin(UFH).2ComparedwithUFH,LMWHsofferthe
FromtheDepartmentsofPathology(CA,OI,DH,JC,EL,JF)andPharmacology(DH,JF),andCardiovascularInstitute(WJ,JMW),LoyolaUniversityMedicalCenter,Maywood,IL.Addresscorrespondenceto:JawedFareed,DepartmentofPathol-ogyandPharmacology,LoyolaUniversityMedicalCenter,2160S.FirstAvenue,Maywood,IL60153;e-mail:jfareed@lumc.edu.convenienceofsubcutaneousadministrationandhavegreaterbioavailability(90%-100%),longerhalf-life(t1/2),amorepredictabledoseresponse,andapotentiallyimprovedsafetyprofile.3,4Low-molecular-weightheparinshavebeenshowntobeeffectiveandwell-toleratedalternativestoUFHintreatingandpreventingVTE.5-10EnoxaparinhasahigherratioofantifactorXatoantifactorIIaactivitythanUFH(4:1).11ThisisapotentialadvantageinthatfactorXagenerationoccursearlierinthecoagu-lationcascade,thusblockingasmallamountofXaresultinginpreventionofthegenerationoflargeramountsofthrombin.LaboratorymonitoringisnotgenerallyrequiredwithLMWHtherapy,exceptinpatientswithrenalinsufficiency.12
501
(most often enoxaparin or nadroparin) for the presence of heparin-induced ...anticoagulant for over 60 years.1 Well-known adverse effects of heparin ...
(most often enoxaparin or nadroparin) for the presence of heparin-induced ...anticoagulant for over 60 years.1 Well-known adverse effects of heparin ...
热门文档